SCHEMBL20135774

SCHEMBL20135774

Cc1nc(CBr)c(C)nc1C=O

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20144422 0.79
SCHEMBL16948187 0.79 KDM4E (0.33)
SCHEMBL1697663 0.79 KCNJ1 (0.37) KCNJ1
SCHEMBL10052570 0.79 ERBB2 (0.32)
SCHEMBL1191060 0.74 EGFR (0.41) KCNJ1
SCHEMBL582880 0.74 ERBB2 (0.31)
SCHEMBL20144423 0.72 BCHE (0.36) KCNJ1
SCHEMBL16948211 0.72
SCHEMBL9798631 0.69 EGFR (0.34) KCNJ1
SCHEMBL20144407 0.69 BCHE (0.42) KCNJ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3321259-B1 NEW PYRAZINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF GUANGZHOU MAGPIE PHARMACEUTICAL CO LTD (CN) 2023-10-04 EP disclosed
US-10703729-B2 Pyrazine derivative, and preparation method and medical use thereof GUANGZHOU MAGPIE PHARMACEUTICALS CO LTD (CN) 2020-07-07 US disclosed
US-20190276413-A1 Pyrazine derivative, and preparation method and medical use thereof GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD. (CN) 2019-09-12 US disclosed
EP-3321259-A1 NEW PYRAZINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF Guangzhou Magpie Pharmaceutical Co., Ltd. (CN) 2018-05-16 EP disclosed
CN-105017165-B A kind of new pyrazines derivatives and preparation method thereof and medical applications 广州喜鹊医药有限公司 2018-04-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276413-A1 Pyrazine derivative, and preparation method and medical use thereof RYR2, RYR1, ORAI1 KCNJ1 134/4885
US-10703729-B2 Pyrazine derivative, and preparation method and medical use thereof RYR2, RYR1, ORAI1 KCNJ1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.